"Cell": Qin Chengfeng/InBev/Wang Youchun team develops a new type of mRNA vaccine for COVID-19

Today, the journal Cell published a new paper on the new crown vaccine online.
a team led by Qin Chengfeng, Dr. Inbee and Wang Youchun has developed a new type of mRNA new crown vaccine.
in mouse and non-human primate models, the vaccine stimulates an immune response and induces the production of neutralizing antibodies.
note, the new vaccine uses advanced formulation technology that can be stored at room temperature for at least a week and remainstable.
is expected to significantly reduce cold chain requirements for vaccine products.
researchers point out in their paper that since the outbreak of the new crown, people have been looking forward to the birth of a safe and reliable vaccine as soon as possible.
mRNA-based vaccines are expected to meet this challenge quickly in many vaccine development technologies.
the world, several new mRNA vaccines have entered human clinical trials, with positive early results.
In this study, scientists used a sequence of amino acids in the receptor binding domain (RBD) of the neo-coronavirus S protein to produce antigens.
cell experiments have also confirmed that mRNA fragments that encode this amino acid sequence can produce high-expression RBD fragments after transfection into a variety of cell lines.
to deliver mRNAs that encode antigens, the researchers used a technique called lipid nanoparticles.
manufactured, these nanospheres containing mRNAs have an average size of less than 90 nanometers and have good morphology.
in mouse models, after receiving one injection, the animals had IgG antibodies against the new coronavirus RBD, as well as antibodies to the neutral and crown virus.
, like several current mRNA vaccines, the levels of these antibodies rose rapidly after the second injection.
, in mice, the injection of the vaccine also induces an immune response of T cells.
researchers have also conducted virus-fighting experiments.
mice that received the vaccine were completely protected after being exposed to the new coronavirus (MASCp6 strain) - neither lung nor trachea had detected viral RNA.
and the control group had a clear viral infection.
in the crab-eating monkey model, the researchers tested it again.
the animals were divided into three groups (10 in each group) with a 100-g vaccine, 1000?g vaccine, and placebo injections.
in the vaccination group, the researchers observed a similar rise in antibodies, as well as a specific T-cell immune response.
, considering that many areas where the new coronavirus is rampant do not have a full cold chain system, the researchers also assessed the vaccine's storage performance at different temperatures.
test results show edited that using this technique, a week's worth of nanolipids stored at 4 or 25 degrees does not affect the reported gene mRNA expression.
stored at 37 degrees for a week, it also reduced the number of reported gene expressionby by only 13%.
combined, these results suggest that the technology can produce a vaccine that is stable at room temperature.
the new mRNA vaccine was approved for clinical trial siton on June 19, according to public information.
()